AstraZeneca Results Presentation Deck
Oncology
Total Revenue ($m)
700
600
500
400
300
200
100
0
■EM
☐EROW
■ Europe
US
Q2
5
3
22
250
Calquence
33% growth at CER to $1,185m in H1 2023
Q3
2021
5
4
37
308
Q4
8
8
43
336
Q1
1353
7
55
339
Q2
8
18
67
396
2022
Q3
12
18
79
457
Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
40 CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World.
Collaboration partners: Daiichi Sankyo (Enhertu).
Q4
17
20
86
465
Q1
18
22
108
384
2023
Q2
24
27
117
485
Total Revenue ($m)
350
300
250
200
150
100
50
0
☐EM
☐EROW
Europe
US
Q2
3
6
40
Enhertu
>2x growth at CER to $580m in H1 2023
Q3
2021
4
9
45
Q4
5
13
49
Q1
9
1
20
57
Q2
APPENDIX | H1 2023 Product Performance
17
2
26
73
2022
Q3
25
2
31
124
Q4
29
3
33
151
Q1
38
3
55
161
2023
Q2
69
5
70
178View entire presentation